tldrdailynews.com logo
Tag

Cell Therapies

All articles tagged with #cell therapies

Lilly strikes $3.25B buyout of Kelonia Therapeutics in high-stakes biotech bet
biotech1 month ago

Lilly strikes $3.25B buyout of Kelonia Therapeutics in high-stakes biotech bet

Eli Lilly agreed to acquire Kelonia Therapeutics for $3.25 billion, with potential additional payments tied to clinical, regulatory, and commercial milestones. Kelonia—formerly Elcano Therapeutics—had survived on about $60 million over five years and nearly ran out of cash on three occasions, aided by Venrock’s early backing. The deal highlights the volatile, milestone-driven journey of biotech startups and the race to capitalize on cell-therapy advances.

via statnews.com|
#acquisition#biotech#cell-therapies
Unveiling the Mysteries of the Dopaminergic System: Insights from Organoid and Assembloid Models
neuroscience2 years ago

Unveiling the Mysteries of the Dopaminergic System: Insights from Organoid and Assembloid Models

Researchers have developed an organoid model that replicates the structure, connectivity, and functionality of the human dopaminergic system, shedding light on Parkinson's disease and the long-term effects of chronic cocaine use. The model shows promise in improving cell therapies for Parkinson's disease and provides insights into addiction research.

via Neuroscience News|
#addiction#cell-therapies#dopaminergic-system
Eli Lilly Acquires Sigilon Therapeutics, Expanding Diabetes Treatments
healthcare2 years ago

Eli Lilly Acquires Sigilon Therapeutics, Expanding Diabetes Treatments

Pharmaceutical company Eli Lilly has announced its plans to acquire the remaining shares of Sigilon Therapeutics, a company specializing in experimental cell therapies for diabetes patients. The deal, valued at $34.6 million in upfront cash, will provide Lilly with access to Sigilon's proprietary cell therapy candidate for treating type 1 diabetes. The acquisition is expected to close in the third quarter of 2023.

via Reuters|
#acquisition#cell-therapies#diabetes-treatments
healthcare2 years ago

Eli Lilly's Acquisition of Sigilon Therapeutics Boosts Diabetes Treatment Portfolio

Eli Lilly and Co announced its plans to acquire the remaining shares of Sigilon Therapeutics to expand its diabetes treatments. The deal, valued at $34.6 million in upfront cash, will give Lilly access to Sigilon's proprietary cell therapy candidate for type 1 diabetes. Sigilon shareholders may receive an additional $111.64 per share based on certain milestones. The acquisition is expected to close in Q3 2023.

via Yahoo Finance|
#acquisition#cell-therapies#diabetes-treatments